
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Shift in Portuguese Pediatric Vaccination Policy: Evolving Perspectives on Risk and Benefit
Portuguese Pediatric Vaccination is now restricted to children with specific high-risk conditions, following the exact approach recommended by pharmaceutical experts in 2021. Portuguese health authorities have abandoned universal COVID-19 vaccination for children, limiting the program to those ag...
Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch
Johnson & Johnson’s launchs the VARIPULSE Pro Platform in Europe. Pulsed field ablation has advanced significantly with the introduction of a new pulse sequence that delivers ablation lesions five times faster than the previous version while maintaining equivalent lesion quality and the estab...
Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities
Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a stron...